Načítá se...
非小细胞肺癌免疫检查点抑制剂治疗相关外周血生物标志物研究进展
Immune checkpoint inhibitors (ICI) have transformed the treatment landscape of advanced non-small cell lung cancer (NSCLC). Biomarkers are essential for guiding precision immunotherapy. Tissue-based programmed death ligand 1 (PD-L1) expression and tumor mutational burden (TMB) are currently widely u...
Uloženo v:
| Vydáno v: | Zhongguo Fei Ai Za Zhi |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
中国肺癌杂志编辑部
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8317092/ https://ncbi.nlm.nih.gov/pubmed/34187157 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.24 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|